An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases may predict the occurrence of severe side effects from immunotherapy in patients with melanoma, according to a recent study published by Monson et al in Clinical Cancer Research.
Health Professionals
Gene signature predicts severe adverse events from ICI therapy for melanoma
The spleen tyrosine kinase pathway was upregulated in patients that had severe toxicities from immune checkpoint inhibitor therapy.
Study links renalase-1 and T-cell receptor interaction to increased melanoma survival
A new research paper was published in Oncotarget’s Volume 15 on August 5, 2024, entitled, “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival."
ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.